FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction

Media coverage

• Title	FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
  Media name/outlet	Plus Company Updates (PCU)
  Country	United States
  Date	10/12/18
  Persons	Antonio R Anzueto

• Title	FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
  Media name/outlet	BioSpace
  Country	United States
  Date	10/11/18
  Persons	Antonio R Anzueto

• Title	FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
  Media name/outlet	PharmiWeb
  Country	United Kingdom
  Date	10/11/18
  Persons	Antonio R Anzueto